I've been at The International Celiac Disease Symposium for the last few days. During a panel discussion on treatment, Thomas Waldmann (a VERY big name in the field) mentioned that he sure would like to have a highly specific JAK1 inhibitor to play around with. So on the break, I showed him the ACR abstract. Seems he's been asking Incyte and other companies what they have cooking pretty regularly, and the answer is always "We can't tell you anything before the public announcement." He's most interested. In addition to CD, he's interested in the possibilities of JAK1 inhibition in various T-cell lymphomas (interesting problem: taken together, there are a lot of cases of T-cell lymphomas. But practically every individual case is a separate subtype. How do you design a trial? What do you want on the label?) I don't know what else is cooking out there, but he'd also like a clean JAK3 inhibitor to play with.